Artivion (NYSE:AORT) SVP Sells $145,188.54 in Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 3,843 shares of the company’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $145,188.54. Following the completion of the transaction, the senior vice president owned 194,057 shares of the company’s stock, valued at approximately $7,331,473.46. This trade represents a 1.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Artivion Price Performance

AORT stock opened at $37.18 on Friday. The company has a market capitalization of $1.78 billion, a P/E ratio of 185.91 and a beta of 1.60. The company has a fifty day moving average price of $41.06 and a 200-day moving average price of $42.84. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.25.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. The company had revenue of $118.30 million for the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The business’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, equities analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AORT. Citizens Jmp increased their price target on Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a research note on Friday, November 7th. Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Canaccord Genuity Group reduced their target price on Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a report on Friday, February 13th. Stifel Nicolaus set a $55.00 target price on shares of Artivion in a research report on Thursday. Finally, Oppenheimer restated an “outperform” rating and set a $50.00 price target on shares of Artivion in a report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $50.47.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in AORT. Aster Capital Management DIFC Ltd raised its position in shares of Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Artivion during the 3rd quarter valued at about $27,000. Larson Financial Group LLC grew its stake in Artivion by 148.5% during the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the period. USA Financial Formulas grew its stake in Artivion by 163.5% during the fourth quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after purchasing an additional 538 shares in the last quarter. 86.37% of the stock is owned by institutional investors.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.